News Regeneron's Inmazeb named Galien's Best Biotech Product The Galien Foundation, which acknowledges “extraordinary scientific innovations that improve the human condition”, has awarded its
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
